FAU.de
Deutsch
Login
Home
Publications
Research Grants
Inventions & Patents
Awards
Additional Research Activities
Faculties & Institutions
Research Areas
Professur für Molekulare Mechanismen der Organfibrose
Reallocation / Closing: 30.09.2022
Friedrich-Alexander-Universität Erlangen-Nürnberg
Medizinische Fakultät
Einrichtungen, die zum Universitätsklinikum Erlangen gehören
Department of Medicine 3 – Rheumatology and Immunology
Lehrstuhl für Innere Medizin III
Overview
Publications
(352)
Research Grants
(2)
Types of publications
Toggle all
Journal article
Journal article
Book chapter / Article in edited volumes
Book chapter / Article in edited volumes
Authored book
Authored book
Translation
Translation
Thesis
Thesis
Edited Volume
Edited Volume
Conference contribution
Conference contribution
Other publication type
Other publication type
Unpublished / Preprint
Unpublished / Preprint
Publication year
From
To
Abstract
Journal
Filters (inactive)
Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis (2020)
Soare A, Györfi AH, Matei AE, Dees C, Rauber S, Wohlfahrt T, Chen CW, et al.
Journal article
Shared and distinct mechanisms of fibrosis (2019)
Distler J, Györfi AH, Ramanujam M, Whitfield ML, Königshoff M, Lafyatis R
Journal article, Review article
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways (2019)
López-Isac E, Acosta-Herrera M, Kerick M, Assassi S, Satpathy AT, Granja J, Mumbach MR, et al.
Journal article
Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course (2019)
Cavagna L, Trallero-Araguas E, Meloni F, Cavazzana I, Rojas-Serrano J, Feist E, Zanframundo G, et al.
Journal article
Regulation of Fibroblast Apoptosis and Proliferation by MicroRNA-125b in Systemic Sclerosis (2019)
Kozlova A, Pachera E, Maurer B, Juengel A, Distler J, Kania G, Distler O
Journal article
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease by Use of Mycophenolate at Baseline: Subgroup Analysis of the SENSCIS Trial (2019)
Highland K, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, et al.
Conference contribution
Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial (2019)
Mayes M, Highland K, Gahlemann M, Fischer A, Raghu G, Girard M, Alves M, et al.
Conference contribution
The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases (2019)
Matteson E, Kelly C, Distler J, Mann-Vold AMH, Seibold J, Mittoo S, Distler O, et al.
Conference contribution
BDCA2 Targeting of Human Plasmacytoid Dendritic Cells via CBS004 Reverts Dependent IFN Activation and Tissue Fibrosis in vitro and in vivo (2019)
Ross R, Corinaldesi C, Migneco G, El-Sherbiny Y, Holmes S, Distler J, Mckimmie C, Del Galdo F
Conference contribution
Cracking a Novel Profibrotic Molecular Mechanism: lncRNA H19X and DDIT4L Crosstalk (2019)
Pachera E, Assass S, Salazar G, Frank-Bertoncelj M, Distler J, Kania G, Distler O
Conference contribution
‹
1
...
13
14
15
16
17
...
36
›